Promega Corporation Expands Availability of FuGENE(R) HD to All Life Science and Applied Markets
MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announces it will provide FuGENE® HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.